-
公开(公告)号：US20240269258A1
公开(公告)日：2024-08-15
申请号：US18627824
申请日：2024-04-05
申请人： SANOFI PASTEUR INC.
发明人： Timothy ALEFANTIS , Mario BARRO , Anthony BYERS , Philip DAVIDSON , Maryann GIEL-MOLONEY , Philippe-Alexandre GILBERT , Harold KLEANTHOUS , Armaghan NAIK , Konstantin PUGACHEV , Saranya SRIDHAR , William WARREN , Konstantin ZELDOVICH
IPC分类号： A61K39/145 , A61K9/00 , A61K39/00 , C07K14/005
CPC分类号： A61K39/145 , A61K9/0019 , C07K14/005 , A61K2039/55555 , A61K2039/70 , C12N2760/16322 , C12N2760/16334
摘要： Disclosed are multivalent vaccine or immunogenic compositions comprising influenza virus hemagglutinin (HA) from standard of care influenza virus strains, or ribonucleic acid molecules encoding the same; and one or more influenza virus HA identified or designed by machine learning, or one or more ribonucleic acid molecules that encode the influenza virus HA identified or designed by machine learning. Also disclosed are methods of using the vaccine or immunogenic compositions.
-
公开(公告)号：US12024553B2
公开(公告)日：2024-07-02
申请号：US16859750
申请日：2020-04-27
发明人： Anis Ahmed Khan , Vadryn Pierre
CPC分类号： C07K16/1027 , A61K47/183 , A61K47/26 , A61P31/14 , A61K2039/545 , C07K2317/21 , C07K2317/76
摘要： In one aspect, this disclosure describes methods of treating or preventing RSV infection in a patient in need thereof. The methods include dosing regiments for administering a composition including a fixed dose of an anti-RSV monoclonal antibody or an antigen binding fragment thereof. In another aspect, this disclosure describes pharmaceutical compositions for the treatment or prevention of RSV infection. In yet another aspect, this disclosure describes a pharmaceutical unit dose including nirsevimab.
-
公开(公告)号：US11970690B2
公开(公告)日：2024-04-30
申请号：US16981200
申请日：2019-03-19
申请人： SANOFI PASTEUR INC.
发明人： Patrick Farrell , Bo Zhi Sun , Fabien Barbirato , Javier de Jesus Menendez Diaz , Andrew Chiappetta
CPC分类号： C12N1/20 , A61K39/099 , C12N1/38 , C12N2500/02 , C12N2500/34 , C12N2500/60 , C12N2500/72
摘要： The present disclosure is directed to a method for cultivating a Bordetella species, comprising: cultivating a Bordetella species under aerobic conditions in a liquid culture medium; and maintaining a pH of the liquid culture medium by using a strong acid, such as nitric acid, or using a first and second acid, wherein the first acid is an inorganic acid that dissociates essentially completely in water, such as nitric acid, hydrochloric acid or sulfuric acid, and wherein the second acid is an inorganic acid having an acid dissociation constant (pKa) of greater than 1, such as phosphoric acid. Methods for increasing the yield of Bordetella fimbrial agglutinogen 2 and fimbrial agglutinogen 3 (FIM2/3) in a supernatant fraction from a Bordetella culture are also provided.
-
公开(公告)号：US20220363724A1
公开(公告)日：2022-11-17
申请号：US17813445
申请日：2022-07-19
申请人： SANOFI PASTEUR INC.
IPC分类号： C07K14/11 , C07K14/005 , C07K16/10 , G01N33/569
摘要： The disclosure provides methods for generating an optimized nucleotide sequence encoding an engineered influenza structural protein and the optimized nucleotide sequences obtained therefrom. The optimized nucleotide sequences can be used in a reverse genetics system to facilitate the rescue of infectious influenza virus containing the engineered structural proteins and/or enhance viral titers. Also provided are methods of preparing an influenza vaccine composition using the optimized nucleotide sequences, as well as methods of inducing an immune response using the influenza vaccine composition.
-
公开(公告)号：US20220204593A1
公开(公告)日：2022-06-30
申请号：US17606614
申请日：2020-04-30
发明人： Anis Ahmed KHAN , Vadryn PIERRE
摘要： In one aspect, this disclosure describes methods of treating or preventing RSV infection in a patient in need thereof. The methods including dosing regimens for administering a composition including a fixed dose of an anti-RSV monoclonal antibody or an antigen binding fragment thereof. In another aspect, this disclosure describes pharmaceutical compositions for the treatment or prevention of RSV infection. In yet another aspect, this disclosure describes a pharmaceutical unit dose including nirsevimab.
-
公开(公告)号：US11325947B2
公开(公告)日：2022-05-10
申请号：US16751963
申请日：2020-01-24
申请人： SANOFI PASTEUR INC.
发明人： Tod Strugnell , Eliud Oloo , Raymond Oomen
IPC分类号： A61K39/145 , C07K14/005 , C07K14/11 , A61K39/00 , A61K39/12 , A61K9/00 , A61K39/39 , C12N9/24
摘要： The present invention provides, among other things, a novel and improved method for generating “mosaic” influenza antigenic polypeptides including hemagglutinin (HA) and neuraminidase (NA) polypeptides based on unique combination of epitope patterns that maximize exposure to epitopes present across multiple HA or NA sequences and therefore improved influenza strain coverage. In particular, the present invention provides engineered H1N1 influenza hemagglutinin (HA) polypeptides that are comprised of novel combinations of protective epitopes and antigenic regions from multiple H1N1 viral strains. Such engineered HA polypeptides have improved properties over HA polypeptides developed through conventional approaches that rely on consensus alignments of viral sequences.
-
公开(公告)号：US11305005B2
公开(公告)日：2022-04-19
申请号：US15738417
申请日：2016-06-23
申请人： Sanofi Pasteur, Inc.
IPC分类号： A61K39/145 , A61K39/12 , A61P29/00 , C12N7/00 , A61K39/00
摘要： This application relates to the field of prevention of pneumonia by administration of a high-dose influenza vaccine.
-
公开(公告)号：US20220054623A1
公开(公告)日：2022-02-24
申请号：US17400390
申请日：2021-08-12
申请人： SANOFI PASTEUR INC.
发明人： Tod Strugnell , Eliud Oloo , Raymond Oomen
IPC分类号： A61K39/145 , A61P31/16 , C07K14/005 , C12N7/00
摘要： The present invention provides, among other things, modified recombinant HA polypeptides with broadened immunogenic profile that extends coverage to antigenically distinct influenza strains and methods of making and using the same.
-
公开(公告)号：US11224652B2
公开(公告)日：2022-01-18
申请号：US16322698
申请日：2017-08-04
发明人： Kyungjun An , Wooyoung Choi , Dongsoo Ham , Hun Kim , Jinhwan Shin , Robert Hopfer , Richard D. Kensinger , Moe Kyaw , Eric Desauziers , Clotilde El Guerche Seblain , Philippe Talaga
摘要： Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 16 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 9V, 12F, 14, 18C, 19A, 19F, 22F, 23F, and 33F, wherein two of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRM197, and wherein the two capsular polysaccharides that are conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3, and 5. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.
-
公开(公告)号：US11123417B2
公开(公告)日：2021-09-21
申请号：US16966584
申请日：2019-02-04
发明人： Kyungjun An , Dongsoo Ham , Hun Kim , Sunghyun Kim , Jinhwan Shin , Robert Hopfer , Richard D. Kensinger , Moe Kyaw , Philippe Talaga
摘要： Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.
-
-
-
-
-
-
-
-
-
搜索结果
88 条记录 (耗时 0.028 秒)
